CAS 412950-08-4

Rilapladib

Description:

Rilapladib is a synthetic compound classified as a small molecule inhibitor, primarily targeting lipoprotein-associated phospholipase A2 (Lp-PLA2). It is designed to modulate inflammatory processes associated with atherosclerosis and cardiovascular diseases. Rilapladib exhibits characteristics typical of a drug candidate, including a specific mechanism of action that aims to reduce the risk of plaque formation in arterial walls. The compound has been investigated in clinical trials for its potential to improve cardiovascular outcomes by inhibiting the enzymatic activity of Lp-PLA2, which is implicated in the inflammatory response related to atherosclerosis. Rilapladib's chemical structure includes functional groups that contribute to its biological activity and pharmacokinetic properties, such as solubility and bioavailability. As with many pharmaceutical agents, its safety profile, efficacy, and potential side effects are evaluated through rigorous clinical testing. Overall, Rilapladib represents a targeted therapeutic approach in the management of cardiovascular diseases, reflecting ongoing research in the field of lipid metabolism and inflammation.

Formula: C₄₀H₃₈F₅N₃O₃S

InChI: InChI=1/C40H38F5N3O3S/c1-51-22-21-46-19-17-32(18-20-46)47(24-27-9-11-28(12-10-27)29-13-15-31(16-14-29)40(43,44)45)37(50)25-48-35-8-3-2-6-33(35)36(49)23-38(48)52-26-30-5-4-7-34(41)39(30)42/h2-16,23,32H,17-22,24-26H2,1H3

InChI key: InChIKey=NNBGCSGCRSCFEA-UHFFFAOYSA-N

SMILES: C(C(N(CC1=CC=C(C=C1)C2=CC=C(C(F)(F)F)C=C2)C3CCN(CCOC)CC3)=O)N4C=5C(C(=O)C=C4SCC6=C(F)C(F)=CC=C6)=CC=CC5

Synonyms:

• 1(4H)-Quinolineacetamide, 2-[[(2,3-difluorophenyl)methyl]thio]-N-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-N-[[4′-(trifluoromethyl)[1,1′-biphenyl]-4-yl]methyl]-
• 2-[[(2,3-Difluorophenyl)methyl]thio]-N-[1-(2-methoxyethyl)-4-piperidinyl]-4-oxo-N-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-1(4H)-quinolineacetamide
• N-[1-(2-Methoxyethyl)piperidin-4-yl]-2-[2-[(2,3-difluorobenzyl)thio]-4-oxo-4H-quinolin-1-yl]-N-[(4′-trifluoromethylbiphenyl-4-yl)methyl]acetamide
• Sb 659032
• Rilapladib
• Unii-o14cwe893z

Rilapladib

CAS: 412950-08-4

Rilapladib

Purity: ≥95%

Molecular weight: 735.8g/mol

Ref: 54-BUP05008

Rilapladib

CAS: 412950-08-4

Rilapladib is an inhibitor of the class of lipoprotein-associated phospholipase A2 (LpPLA2) that has a potent inhibitory effect on the synthesis of pro-inflammatory and pro-thrombotic mediators. Rilapladib is a lipid-lowering drug that inhibits LpPLA2, which is involved in the production of inflammatory and thrombotic mediators. The clinical efficacy and safety of rilapladib has been studied in patients with coronary artery disease who are at risk for cardiovascular events. Results from these studies reveal that rilapladib can reduce the risk of cardiovascular events.

Formula: C₄₀H₃₈F₅N₃O₃S

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 735.81 g/mol

Ref: 3D-FR104267

Rilapladib

CAS: 412950-08-4

Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2(Lp-PLA2, IC50 = 230 pM) and an antagonist of the platelet activating

Formula: C₄₀H₃₈F₅N₃O₃S

Purity: 99.92%

Color and Shape: Solid

Molecular weight: 735.8

Ref: TM-T16751